A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations

Trial Profile

A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Entrectinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Registrational
  • Acronyms STARTRK-1
  • Sponsors Ignyta
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
    • 13 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
    • 06 Sep 2017 According to an Ignyta media release, the company is on track to submit an NDA filing in the ROS1 NSCLC indication in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top